The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
Authors
Martinez-Soria, NMcKenzie, L
Draper, Julia E
Ptasinska, A
Issa, H
Potluri, S
Blair, HJ
Pickin, A
Isa, A
Chin, PS
Tirtakusuma, R
Coleman, D
Nakjang, S
Assi, S
Forster, V
Reza, M
Law, E
Berry, P
Mueller, D
Elder, A
Bomken, SN
Pal, D
Allan, JM
Veal, GJ
Cockerill, PN
Wichmann, C
Vormoor, J
Lacaud, Georges
Bonifer, C
Heidenreich, O
Affiliation
Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Brewery Lane, Newcastle upon Tyne NE1 7RU, UKIssue Date
2018
Metadata
Show full item recordAbstract
Oncogenic transcription factors such as the leukemic fusion protein RUNX1/ETO, which drives t(8;21) acute myeloid leukemia (AML), constitute cancer-specific but highly challenging therapeutic targets. We used epigenomic profiling data for an RNAi screen to interrogate the transcriptional network maintaining t(8;21) AML. This strategy identified Cyclin D2 (CCND2) as a crucial transmitter of RUNX1/ETO-driven leukemic propagation. RUNX1/ETO cooperates with AP-1 to drive CCND2 expression. Knockdown or pharmacological inhibition of CCND2 by an approved drug significantly impairs leukemic expansion of patient-derived AML cells and engraftment in immunodeficient murine hosts. Our data demonstrate that RUNX1/ETO maintains leukemia by promoting cell cycle progression and identifies G1 CCND-CDK complexes as promising therapeutic targets for treatment of RUNX1/ETO-driven AML.Citation
Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, et al. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell [Internet]. 2018 Oct;34(4):626�642.e8.Journal
Cancer CellDOI
10.1016/j.ccell.2018.08.015PubMed ID
30300583Additional Links
https://dx.doi.org/10.1016/j.ccell.2018.08.015Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ccell.2018.08.015
Scopus Count
Collections
Related articles
- RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
- Authors: Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C
- Issue date: 2019 Sep 17
- Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
- Authors: Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C
- Issue date: 2012 Aug
- The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
- Authors: Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS
- Issue date: 2008 Dec 1
- RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
- Authors: DeKelver RC, Lewin B, Weng S, Yan M, Biggs J, Zhang DE
- Issue date: 2014 Apr
- Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
- Authors: Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH
- Issue date: 2012 Jul 26